Medigen Biotechnology Corp. (TPEX:3176)
Taiwan
· Delayed Price · Currency is TWD 28.90
+0.20 (0.70%)
Apr 24, 2025, 1:30 PM CST
Medigen Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -204.69 | -561.3 | -675.87 | -52.61 | -337.92 | Upgrade
|
| Depreciation & Amortization | 172.31 | 175.77 | 189.13 | 196.35 | 217 | Upgrade
|
| Other Amortization | 14.1 | 32.87 | 21.87 | 2.08 | 1.84 | Upgrade
|
| Loss (Gain) From Sale of Assets | -69.27 | 1.03 | - | 0.25 | -19.95 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.44 | 9.58 | 16.66 | -10.92 | 2.42 | Upgrade
|
| Loss (Gain) on Equity Investments | 28.44 | 92.26 | 262.21 | 98.8 | 54.57 | Upgrade
|
| Stock-Based Compensation | - | 22.37 | 82.07 | 77.4 | 54.87 | Upgrade
|
| Provision & Write-off of Bad Debts | 6.48 | 14.44 | 21.13 | -20.49 | -3.17 | Upgrade
|
| Other Operating Activities | 86.5 | -800.48 | -1,220 | 1,181 | -545.47 | Upgrade
|
| Change in Accounts Receivable | 13.86 | 43.35 | 443.69 | -650.83 | 22.77 | Upgrade
|
| Change in Inventory | -97.83 | 145.92 | 60.29 | -429.02 | -187.54 | Upgrade
|
| Change in Accounts Payable | -0.61 | -74.37 | 30.8 | 53.83 | 39.09 | Upgrade
|
| Change in Unearned Revenue | 95.37 | 4.6 | -114.03 | 130.5 | 11.78 | Upgrade
|
| Change in Other Net Operating Assets | -5.3 | 336.49 | -255.21 | -58.37 | -18.49 | Upgrade
|
| Operating Cash Flow | 37.92 | -503.52 | -1,138 | 518.12 | -687.6 | Upgrade
|
| Capital Expenditures | -54.85 | -38.41 | -148.16 | -142.96 | -132.64 | Upgrade
|
| Sale of Property, Plant & Equipment | 156.87 | - | - | 126 | 24.65 | Upgrade
|
| Sale (Purchase) of Intangibles | -2.17 | -3.49 | -3.21 | -1.59 | -7.65 | Upgrade
|
| Investment in Securities | 802.02 | 492.47 | -2,297 | -879.7 | -104.49 | Upgrade
|
| Other Investing Activities | 1.42 | 47.09 | -4.54 | -12.25 | -16.95 | Upgrade
|
| Investing Cash Flow | 903.3 | 497.66 | -2,453 | -910.5 | -237.09 | Upgrade
|
| Short-Term Debt Issued | 118.9 | 210 | 308 | 370 | 412 | Upgrade
|
| Long-Term Debt Issued | 67.5 | 29.7 | 1,755 | - | 10 | Upgrade
|
| Total Debt Issued | 186.4 | 239.7 | 2,063 | 370 | 422 | Upgrade
|
| Short-Term Debt Repaid | -291.7 | -135.4 | -280 | -545 | -312 | Upgrade
|
| Long-Term Debt Repaid | -1,847 | -28.23 | -28.91 | -22.49 | -471.82 | Upgrade
|
| Total Debt Repaid | -2,139 | -163.63 | -308.91 | -567.49 | -783.82 | Upgrade
|
| Net Debt Issued (Repaid) | -1,952 | 76.07 | 1,754 | -197.49 | -361.82 | Upgrade
|
| Issuance of Common Stock | 3.4 | 3.29 | 2.41 | 11.27 | 4.45 | Upgrade
|
| Repurchase of Common Stock | - | -18.59 | - | - | - | Upgrade
|
| Other Financing Activities | 175.61 | 132.39 | 1,734 | 517.57 | 2,669 | Upgrade
|
| Financing Cash Flow | -1,773 | 193.15 | 3,490 | 331.35 | 2,311 | Upgrade
|
| Foreign Exchange Rate Adjustments | -3.26 | -5 | -3.08 | -0.96 | 6.34 | Upgrade
|
| Net Cash Flow | -835.21 | 182.29 | -103.95 | -62 | 1,393 | Upgrade
|
| Free Cash Flow | -16.93 | -541.93 | -1,286 | 375.16 | -820.23 | Upgrade
|
| Free Cash Flow Margin | -1.23% | -46.81% | -121.82% | 9.57% | -133.25% | Upgrade
|
| Free Cash Flow Per Share | -0.12 | -3.89 | -9.25 | 2.70 | -5.90 | Upgrade
|
| Cash Interest Paid | 25.22 | 25.61 | 20.1 | 19.07 | 31.88 | Upgrade
|
| Cash Income Tax Paid | 56.06 | 40.23 | 23.35 | 8.37 | 0.36 | Upgrade
|
| Levered Free Cash Flow | 27.25 | -190.22 | -660.21 | -246.5 | -820.31 | Upgrade
|
| Unlevered Free Cash Flow | 38.82 | -185.56 | -654.91 | -234.58 | -800.38 | Upgrade
|
| Change in Net Working Capital | -42.18 | -426.28 | -264.61 | 853.33 | 363.61 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.